PROVIDER BULLETIN PROVIDER INFORMATION



May 25, 2017

New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Antifungal Agents Effective August 1, 2017, Blue Cross and Blue Shield of Minnesota and Blue Plus (Blue Cross) will require PA with QL for selected antifungal agents.

The intent of the Antifungal PA program is to ensure that patients' prescribed therapy meet the selection requirements defined in product labeling and/or clinical guidelines and/or clinical studies. The PA defines appropriate use for the treatment of onychomycosis as a confirmed fungal nail infection that is considered medically necessary to treat.

As stewards of healthcare expenditures for our subscribers, we are charged with ensuring the highest quality, evidence-based care. One method for doing so is through the PA process. The primary purpose of the PA process is to ensure that evidence based care is provided to our subscribers, driving quality, safety, and affordability.

Antifungal Agents - Prior Authorization with Quantity Limit	Quantity Limit (per 30 days)
JUBLIA® (efinaconazole)	4 mL
KERYDIN® (tavaborole)	4 mL
LAMISIL® (terbinafine) tab	30 tabs
LAMISIL® (terbinafine) granules packet	30 packets
ONMEL® (itraconazole)	30 tabs
PENLAC® (ciclopirox)	6.6 mL
SPORANOX® (itraconazole) cap	120 caps
SPORANOX® (itraconazole) 10 mg/mL oral solution	1200 mL
TERBINEX TM (terbinafine)	30 tabs

Products impacted

This PA program applies to commercial lines of business and the following Minnesota Health Care Programs:

- Blue Advantage Prepaid Medical Assistance Program (PMAP)
- Minnesota Senior Care Plus (MSC+)
- MinnesotaCare

New PA criteria will be posted by July 1, 2017, and can be accessed using the Blue Cross provider link.

- Access providers.bluecrossmn.com
- Under Tools and Resources, select Medical policy, then acknowledge the Acceptance statement
- Select Utilization Management
- Select Pharmacy Utilization Management Programs

CoverMyMeds prior authorization request service

As a reminder, CoverMyMeds (CMM) is a free service to providers which allows quick and easy submission of PA requests. Experience with CMM by other plans has demonstrated marked reductions in physician office call-backs regarding PA requests, after CMM is implemented. PA requests may also continue to be faxed to their review destination external to the CMM portal, as is the current practice.

You may access CMM at www.covermymeds.com. Select Help (top right of the web page) to view FAQs and Support tutorials (3-5 minutes), including live online chat support to help you get started. You will need to open a CMM account to submit requests using the portal.

Questions?

If you have questions, please contact provider services at (651) 662-5200 or 1-800-262-0820.

P27-17

Distribution: All participating providers impacted by the information in this bulletin. https://www.bluecrossmn.com/healthy/public/personal/home/providers/forms-and-publications